Recurrence-Associated Multi-RNA Signature to Predict Disease-Free Survival for Ovarian Cancer Patients

Figure 4

Kaplan–Meier survival curves for patients with different pathologic staging. (a) Prognostic value of pathologic stage; (b–d) prognostic value of multi-RNA-based risk score model stratified by pathologic staging ((b) stage 2; (c) stage 3; (d) stage 4). HR, hazard ratio.

(a)

(b)

(c)

(d)